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Supplemental Methods: 
Breeding strategy to produce Pparg-/-epi and WT sibling controls.  
Mice containing a Cre recombinase driven by a cytokeratin 14 promoter (Tg(KRT14-
cre)1Amc/J) and mice containing loxP sites flanking exons 1 & 2 of the Pparg allele (B6.129-
Ppargtm2Rev/J) were purchased from the Jackson Laboratory (Bar Harbor, Maine).  Both mouse 
strains were backcrossed into the SKH1 mouse strain for 6 generations. To generate both 
conditional knockouts and WT sibling controls, 6th generation SKH-1 mice hemizygous for the 
floxed Pparg allele (Pparg(f/wt)) were crossed with 6th generation SKH-1 backcross mice 
hemizygous for the KRT14-Cre allele (KRT14-Cre(+/-)).  Double hemizgyous pups 
(Pparg(f/wt)/ KRT14-Cre(+/-)) were then selected and crossed.  In this next generation, pups 
that had the genotype Pparg(f/f)/KRT14-Cre(+/-) or Pparg(f/f)/KRT14-Cr(-/-) were then 
selected.  These were then crossed to generate conditional knockouts (Pparg(f/f)/KRT14-Cre(+/-
)) or wildtype sibling controls (Pparg(f/f)/KRT14-Cre(-/-)). Given that the presence or absence 
of the KRT14-Cre recombinase differentiates WT from conditional knockouts, all experimental 
mice were genotyped twice, both prior to and after experimental use to verify the presence or 
absence of the KRT14-Cre allele. 
Detailed description of chronic UVB irradiations. 
For all UVB studies, the UVB intensity was measured at a set distance prior to each experiment 
using a IL1700 radiometer equipped with a SED240 UVB detector (International Light, 
Newburyport, MA).  The time of exposure for irradiation was calculated from the intensity 
(fluence) of the lamp and the required UVB dose.  For chronic UVB studies, each cage was 
rotated to a different lamp location for each successive irradiation to avoid variations in fluence 
across the lamp length,. 
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Modified Tumor Classification Scheme. 
Briefly, modifications to the grading of stage 1-3 microinvasive squamous cell carcinomas 
(MISCC) were as follows:  Stage 1 MISCC showed definite invasion into the dermis but no 
invasion into the dermal fat layer while stage 2 MISCC had invasion into the dermal fat layer. 
Stage 3 MISCC showed invasion adjacent to but not into the panniculus carnosus.  Invasive 
squamous cell carcinomas showed invasion into or through the panniculus carnosus.  Given the 
extensive field changes in the Pparg-/-epi mice, it was difficult at times to separate individual 
tumors for classification purposes. When evaluating the slides, additional tumors were not 
assigned unless there was a distinct change in appearance of the tumors in adjacent areas (i.e. 
two papillomas immediately adjacent to one another but each with its own distinct appearance 
and clearly two separate growths), a change in stage (i.e. stage 1 adjacent to a stage 2) or growths 
with an intervening benign appearing epidermis. 
Topical GW9662 treatments.  
The dorsal epidermis of SKH-1 mice was treated with 100 µl of 1, 10, or 100 nanomoles 
(nmoles) of GW9662 solubilized in 70% propylene glycol:30% ethanol for 1.5 hours prior to 
UVB irradiation.  Prior to irradiation, the dorsal skin was wiped gently 4 times with cotton swabs 
soaked in 100% ethanol to remove non-absorbed reagents.  Immediately following irradiation, 50 
µl of GW9662 (0.5, 5 or 50 nmole) was reapplied to the dorsal skin of the mouse (total additive 
dose between the pre- and post-treatment = 1.5, 15 or 150 nmoles).  For the 72 hour time point, 
50 µl of vehicle or GW9662 (0.5 or 5 nmole) was reapplied to the dorsal epidermis daily (24 and 
48 hrs) for each respective treatment group (total cumulative dose over 72 hrs = 2.5 or 25 
nmoles).   
Tissue cytometric analysis. 
Mice lacking epidermal PPARγ exhibit a marked augmentation in 
photocarcinogenesis associated with increased UVB-induced apoptosis, 
inflammation and barrier dysfunction R.P. Sahu et al. 
 
Tissue cytometric analysis was by done by first identifying individual cell nuclei by DAPI 
staining.  Mean cell intensity for FITC labeling was used to identify epidermal (cytokeratin +) 
and dermal (cytokeratin neg) cells (supplemental figure 5B). Finally, cells double positive for 
Ki67 or p53 and pan-cytokeratin were identified using user-defined cutoffs and verified by back-
directional gating (see supplemental figure 5C & D).  Image analysis was done on at least 7 
random 200x fields from each mouse.     
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Supplemental Figure 1: Loss of epidermal PPARγ results in a trend towards a greater 
percentage of small tumors (<2 mm) and a reduced percentage of intermediate and large 
tumors. Tumor sizes after 24 weeks of UVB treatment were separated into the bin size 
distributions shown based on the greatest tumor diameter.  For each mouse, the number of 
tumors of each bin as a percentage of that mouse's total tumor count were calculated, then the 
mean ± SEM were calculated for each genotype.   The Pparg-/-epi mice exhibited a strong 
statistical trend towards an increased percentage of smaller tumors (1-2 mm bin size) (p=0.056, 
2-tailed t-test). By 2-way ANOVA, the interaction between genotype and the three different 
tumor bin sizes was significant (p = 0.0128).  
Supplemental Figure 2:  Representative images of Pparg-/-epi mice showing increased Ki67 
immunolabeling after 24 weeks of chronic UVB irradiation.   Immunofluorescent staining 
was performed for Ki67 (Red) and for pan-cytokeratin (Green), with DAPI counterstain (Blue).  
Merged images of photomicrographs taken at 200x magnification are shown for (A) Non-
irradiated WT. (B) Non-irradiated Pparg-/-epi. (C) UVB-irradiated WT. (D) UVB-irradiated 
Pparg-/-epi mouse skin.  Quantitation of Ki67 immunolabeling is shown in figure 3A.   
Supplemental Figure 3:  Representative images of Pparg-/-epi mice showing increased 
positivity for p53 following 24 weeks of UVB irradiation.  Immunofluorescence double 
labeling for  p53 (Red) and pan-cytokeratin (Green), with DAPI (Blue) counterstain. Merged 
images of photomicrographs taken at 200x magnification are shown for: (A) UVB-irradiated 
WT. (B) UVB-irradiated Pparg-/-epi. (C) Grayscale image of the p53+ immunolabeling from 
panel (A).  (D) Grayscale image of the p53+_immunolabeling from panel (B).  Non-irradiated 
skin was negative for p53+ (not shown).  Quantitation of p53 immunopositivity is shown in 
figure 3B.   
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Supplemental Figure 4: Depiction of the tissue cytometric analysis. (A) UVB-irradiated 
Pparg-/-epi skin section double labeled for p53 (Alexa Fluor 594-Red) and a FITC-conjugated 
pan-cytokeratin antibody (Green) as described in Methods.  Nuclei were then counterstained 
with DAPI (Blue).  (B) Using tissue cytometric analysis software, cell nuclei were detected by 
DAPI staining and DAPI positive nuclei were assessed for colabeling for median DAPI intensity 
(x-axis) and FITC (y-axis). The cutoff defined the pan-cytokeratin positive (epidermis) from the 
pan-cytokeratin negative (dermal) cells.  (C)  Scattergram showing double-labeling cutoffs for 
FITC (pan-cytokeratin; x-axis) and Alexa Fluor 594 (TR, p53+; y-axis).  (D) Backgating of 
FITC+TR double positive cells to show localization in the p53+ unmerged image.   
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